Free Trial
NASDAQ:PACB

Pacific Biosciences of California (PACB) Stock Price, News & Analysis

Pacific Biosciences of California logo
$2.17
+0.01 (+0.46%)
(As of 10/31/2024 ET)

About Pacific Biosciences of California Stock (NASDAQ:PACB)

Key Stats

Today's Range
$2.07
$2.24
50-Day Range
$1.32
$2.17
52-Week Range
$1.16
$10.65
Volume
8.06 million shs
Average Volume
9.35 million shs
Market Capitalization
$591.39 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.50
Consensus Rating
Moderate Buy

Company Overview

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-red sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, it provides revio system + sequel systems which conduct, monitor, and analyze single-molecule biochemical reactions in real time; SBB short-read sequencing; onso instrument conducts, monitors, and analyzes SBB biochemical reactions; and SBB consumable, including flow cells, clustering, and sequencing reagent kits. The company serves academic and governmental research institutions; commercial testing and service laboratories; genome centers; public health labs, hospitals and clinical research institutes, and contract research organizations; pharmaceutical companies; and agricultural companies. It markets its products through a sales force and distribution partners in Asia, Australia, Europe, the Middle East, Africa, and Latin America. It has a development and commercialization agreement with Invitae Corporation; and a collaboration with Radboud University Medical to explore genetic causes of rare and genetic diseases. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.

Pacific Biosciences of California Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
57th Percentile Overall Score

PACB MarketRank™: 

Pacific Biosciences of California scored higher than 57% of companies evaluated by MarketBeat, and ranked 533rd out of 993 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Pacific Biosciences of California has received a consensus rating of Moderate Buy. The company's average rating score is 2.53, and is based on 8 buy ratings, 7 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Pacific Biosciences of California has only been the subject of 4 research reports in the past 90 days.

  • Read more about Pacific Biosciences of California's stock forecast and price target.
  • Earnings Growth

    Earnings for Pacific Biosciences of California are expected to grow in the coming year, from ($0.95) to ($0.70) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Pacific Biosciences of California is -1.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Pacific Biosciences of California is -1.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Pacific Biosciences of California has a P/B Ratio of 0.83. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Pacific Biosciences of California's valuation and earnings.
  • Percentage of Shares Shorted

    17.81% of the outstanding shares of Pacific Biosciences of California have been sold short.
  • Short Interest Ratio / Days to Cover

    Pacific Biosciences of California has a short interest ratio ("days to cover") of 5.9.
  • Change versus previous month

    Short interest in Pacific Biosciences of California has recently decreased by 6.00%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Pacific Biosciences of California does not currently pay a dividend.

  • Dividend Growth

    Pacific Biosciences of California does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    17.81% of the outstanding shares of Pacific Biosciences of California have been sold short.
  • Short Interest Ratio / Days to Cover

    Pacific Biosciences of California has a short interest ratio ("days to cover") of 5.9.
  • Change versus previous month

    Short interest in Pacific Biosciences of California has recently decreased by 6.00%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Pacific Biosciences of California has a news sentiment score of 0.31. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.68 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 7 news articles for Pacific Biosciences of California this week, compared to 4 articles on an average week.
  • Search Interest

    24 people have searched for PACB on MarketBeat in the last 30 days. This is an increase of 85% compared to the previous 30 days.
  • MarketBeat Follows

    9 people have added Pacific Biosciences of California to their MarketBeat watchlist in the last 30 days. This is an increase of 29% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Pacific Biosciences of California insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $105,647.00 in company stock.

  • Percentage Held by Insiders

    Only 2.40% of the stock of Pacific Biosciences of California is held by insiders.

  • Read more about Pacific Biosciences of California's insider trading history.
Receive PACB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pacific Biosciences of California and its competitors with MarketBeat's FREE daily newsletter.

PACB Stock News Headlines

625,000% Gain
Imagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.
PacBio announces SPRQ chemistry for Revio sequencing systems
See More Headlines

PACB Stock Analysis - Frequently Asked Questions

Pacific Biosciences of California's stock was trading at $9.81 at the beginning of 2024. Since then, PACB stock has decreased by 77.9% and is now trading at $2.17.
View the best growth stocks for 2024 here
.

Pacific Biosciences of California, Inc. (NASDAQ:PACB) released its earnings results on Wednesday, August, 7th. The biotechnology company reported ($0.20) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.24) by $0.04. The biotechnology company had revenue of $36.01 million for the quarter, compared to the consensus estimate of $40.52 million. Pacific Biosciences of California had a negative trailing twelve-month return on equity of 40.98% and a negative net margin of 211.99%.

The following companies are subsidiaries of Pacific Biosciences of California: Circulomics, Omniome, PacBio Singapore PTE Limited, Pacific Biosciences Canada Limited, Pacific Biosciences Germany GmbH, Pacific Biosciences Japan GK, Pacific Biosciences (Shanghai) Co. Ltd., Pacific Biosciences UK Limited, and Pacific Biosciences International LLC.

Top institutional investors of Pacific Biosciences of California include Assenagon Asset Management S.A. (0.10%), Mirador Capital Partners LP (0.08%), Carret Asset Management LLC (0.06%) and IQ EQ FUND MANAGEMENT IRELAND Ltd (0.02%). Insiders that own company stock include Oene Mark Van, Jeff Eidel, Susan G Kim, Michele Farmer, William W Ericson, Kathy Ordonez and Peter Fromen.
View institutional ownership trends
.

Shares of PACB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Pacific Biosciences of California investors own include Tesla (TSLA), NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Netflix (NFLX), Block (SQ) and Alphabet (GOOG).

Company Calendar

Last Earnings
8/07/2024
Today
10/31/2024
Next Earnings (Confirmed)
11/07/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Analytical instruments
Sub-Industry
Life Sciences Tools & Services
Current Symbol
NASDAQ:PACB
CUSIP
69404D10
Employees
730
Year Founded
2004

Price Target and Rating

Average Stock Price Target
$4.50
High Stock Price Target
$12.00
Low Stock Price Target
$2.00
Potential Upside/Downside
+106.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.53
Research Coverage
15 Analysts

Profitability

Net Income
$-306,730,000.00
Net Margins
-211.99%
Pretax Margin
-218.04%

Debt

Sales & Book Value

Annual Sales
$188.87 million
Book Value
$2.62 per share

Miscellaneous

Free Float
265,988,000
Market Cap
$594.11 million
Optionable
Optionable
Beta
2.05

Social Links

Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

This page (NASDAQ:PACB) was last updated on 10/31/2024 by MarketBeat.com Staff
From Our Partners